Last reviewed · How we verify
Vonoprazan+amoxicillin+clarithromycin 14 days
This triple-therapy combination eradicates Helicobacter pylori by suppressing gastric acid with vonoprazan while amoxicillin and clarithromycin attack the bacteria directly.
This triple-therapy combination eradicates Helicobacter pylori by suppressing gastric acid with vonoprazan while amoxicillin and clarithromycin attack the bacteria directly. Used for Helicobacter pylori eradication in peptic ulcer disease, H. pylori-associated chronic gastritis.
At a glance
| Generic name | Vonoprazan+amoxicillin+clarithromycin 14 days |
|---|---|
| Sponsor | Xijing Hospital of Digestive Diseases |
| Drug class | Proton pump inhibitor (vonoprazan) + beta-lactam antibiotic (amoxicillin) + macrolide antibiotic (clarithromycin) |
| Target | H+/K+-ATPase (vonoprazan); bacterial cell wall (amoxicillin); bacterial ribosome (clarithromycin) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Vonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits the H+/K+-ATPase pump to reduce gastric acid secretion, creating an environment where amoxicillin and clarithromycin can effectively penetrate and kill H. pylori. Amoxicillin is a beta-lactam antibiotic that disrupts bacterial cell wall synthesis, while clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis. The combination achieves high eradication rates through synergistic bactericidal and bacteriostatic mechanisms.
Approved indications
- Helicobacter pylori eradication in peptic ulcer disease
- H. pylori-associated chronic gastritis
Common side effects
- Diarrhea
- Nausea
- Abdominal discomfort
- Taste disturbance
- Headache
- Allergic reaction (amoxicillin)
Key clinical trials
- Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial (NA)
- Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1 (PHASE4)
- Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy (PHASE4)
- Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial (PHASE4)
- Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Eradication (PHASE4)
- Comparison of Omeprazole vs Vonoprazon in Treatment of H Pylori Infection (PHASE4)
- 7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication (PHASE3)
- Efficacy and Safety of Black Seed Oil With Vonoprazan Based Triple Therapy in Treatment of Helicobacter Pylori (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: